Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2019. (more…)
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it will release its preliminary results for the year ended 30 June 2019 on 21 October 2019.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. To download this report as a PDF file click here.
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares.